Kardigan (KARD)
Develops cardiovascular therapies through biologically defined, data-enabled clinical trials.
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
Kardiganâ¢, Inc. (Nasdaq: KARD) (âKardiganâ or âthe Companyâ), a clinical-stage precision therapeutics company developing medicines that target the roo
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #CVD--Kardigan™, Inc. (Nasdaq: KARD) today reported financial results from the second quarter ended June 30, 2026, and provided recent business updates.
Kardigan Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)---- $KARD #Kardigan--Kardigan announced the closing of its initial public offering.
Heart drug developer Kardigan targets $1.4 billion valuation in US IPO
Kardigan is targeting a valuation of up to $1.4 billion in its initial public offering in the United States, the drug developer said on Thursday.
Kardigan Begins Process For IPO On Cardiovascular Treatments Promise
Kardigan, Inc. (KARD) is a clinical-stage biopharma targeting various cardiovascular disease treatments with a pipeline led by Danicamtiv, now in Phase 2b/3 trials. KARD leverages its Prolario AI platform to optimize clinical trial design, patient identification, and data collection, aiming for improved outcomes and efficiency. The company is well-capitalized with $287 million in cash and strong backing from top-tier life science VCs, positioning it for robust pipeline advancement.